TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03907891

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational social support from nurse
Description: A 60-minute motivational interviewing session with a nurse, followed by 6 weeks of daily motivational social support text messages.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational social support from nurse with additional support from significant other
Description: A 60-minute motivational interviewing session with a nurse, followed by 6 weeks of daily motivational social support text messages from both a nurse and the patient's self-identified significant other.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention control
Description: A 60-minute session with a nurse focused on American Heart Association educational videos and written information.
Study: NCT03371225

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: Active tDCS: A 1x1 Low-intensity DC Stimulator will be used to deliver direct current through rubber electrodes in saline soaked sponges. The anode will be placed over the left primary motor cortex (M1) while the cathode will be placed over the contralateral supra-orbital area. 20 minutes of tDCS will be applied.
Study: NCT03449459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aerosol inhaled amikacin
Description: 0.4g Amikacin sulfate injection + 5ml saline, aerosol inhalation, b.i.d., 5-7 days per month, for 3 months.~In order to observe and cope with adverse events timely, subjects will be admitted to the ward during the course of medication.~Subjects will take conventional therapy at the same time.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: combined vaccination
Description: Influenza Vaccine recommended by World Health Organization(WHO) in that year and imported 23-Valent Pneumococcal Polysaccharide Vaccine approved by China Food and Drug Administration(CFDA) are vaccinated at different body sites by professional nurses.~The interval between two vaccinations is 3-5 days to avoid the overlap of adverse events.~Subjects will take conventional therapy at the same time.
Study: NCT00185484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)
Description: Oral administration of YAZ (0.02mg ethinyl estradiol-ß-cyclodextrin clathrate and 3mg drospirenone, 24 day hormone tablets followed by 4 days of placebo tablets for 13 cycles
Study: NCT03371225

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active tDCS
Description: Active tDCS: A 1x1 Low-intensity DC Stimulator will be used to deliver direct current through rubber electrodes in saline soaked sponges. The anode will be placed over the left primary motor cortex (M1) while the cathode will be placed over the contralateral supra-orbital area. 20 minutes of tDCS will be applied.
Study: NCT03498040

Intervention type: OTHER
Intervention: Study of the occurrence of Carcinoid Heart Disease
Description: Patient at high risk of Carcinoid Heart Disease (metastatic ileum or bronchial well-differentiated neuroendocrine tumors, patients with high level of urinary 5HIAA or with carcinoid syndrome) are followed with annual echocardiography to detect the occurrence of carcinoid heart disease.~In case of documented Carcinoid Heart Disease, a six or three months' cardiac follow-up is necessary to evaluate the progression and the severity of the disease.~Investigators collect the data of clinical parameters (flushes, diarrhea, ...) biological parameters (urinary 5HIAA, NT-ProBNP ...) and cardiac parameters that may influence the occurrence, severity and progression of Carcinoid Heart Disease.
Study: NCT01511536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel XRP6258
Description: Pharmaceutical form:solution Route of administration: injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel XRP6258
Description: Pharmaceutical form:solution Route of administration: injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel XRP6258
Description: Pharmaceutical form:solution Route of administration: injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Pharmaceutical form:tablets Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Pharmaceutical form:tablets Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Pharmaceutical form:tablets Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone 5 mg
Description: Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone 5 mg
Description: Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone 5 mg
Description: Route of administration: oral
Study: NCT02357758

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic Prophylaxis
Description: Approved clinical dosage or antibiotics
Study: NCT00950053

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Achilles decompression & debridement
Description: Surgical intervention

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Achilles decompression and debridement with FHL transfer
Description: surgical intervention
Study: NCT03941301

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light therapy
Description: Participants will be exposed to bright treatment light or red light 30 minutes every day for 4 weeks.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Light therapy
Description: Participants will be exposed to bright treatment light or red light 30 minutes every day for 4 weeks.
Study: NCT04314128

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: TOS and TCD
Description: TOS: Transorbital sonography TCD: Transcranial Doppler
Study: NCT03076801

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choral Singing
Description: In addition to usual medical care, participants in the intervention group will participate in weekly 60-90 minute singing sessions led by professional musicians over a 12-week period. Sessions will begin with a 5-minute physical warm-up of gentle stretching and a 5-minute vocal warm-up. Music will be selected from a variety of genres and eras. Attendance will be taken weekly.
Study: NCT02046642

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Maternal rest in left lateral position
Description: After initial amniotic fluid index measurements, the participating pregnant women were instructed to turn their left sides and rest in that position for 15 minutes before a second amniotic fluid index measurement
Study: NCT03371225

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Active Exercise
Description: Participants will walk briskly in a treadmill (as to keep at 60-70% maximum heart rate) for 30 minutes
Study: NCT02046642

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Maternal rest in right lateral position
Description: After initial amniotic fluid index measurements, the participating pregnant women were instructed to turn their right sides and rest in that position for 15 minutes before a second amniotic fluid index measurement
Study: NCT02685293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFF MDI (PT003)
Description: Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo MDI
Description: Placebo Metered Dose Inhaler (MDI) for Glycopyrronium and Formoterol Fumarate Inhalation Aerosol
Study: NCT04285086

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ropeginterferon alfa-2b
Description: Ropeginterferon alfa-2b (P1101) dosage: from 250 mcg to 500 mcg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anagrelide
Description: Anagrelide dosage: 0.5 mg per capsule, according to label and physician's judgement
Study: NCT01174992

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evicel
Description: EVICEL is a human plasma derived fibrin sealant

Intervention type: OTHER
Group type: OTHER
Intervention: Sutures only
Description: Standard of care
Study: NCT00031447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyclovir
Description: Oral suspension 300 mg/m\^2/dose, 3 times per day (TID), for 6 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo identical to oral acyclovir suspension in appearance and taste.
Study: NCT01161160

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' GSK2340274A (two different formulations)
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' GSK2340274A (two different formulations)
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' - GSK2340272A
Description: Intramuscular injection
Study: NCT01188122

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AnapnoGuard 100
Description: Respiratory guard system during mechanical ventilation
Study: NCT00554164

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (R-)CHOP protocol
Description: Patients with a persistently positive interim-PET scan assigned to arm B1 will receive another six cycles of the (R-)CHOP regimen (rituximab, cyclophosphamide, doxorubicine, vincristine, prednisone).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B-ALL protocol
Description: Patients with a persistently positive interim-PET scan assigned to arm B2 will receive six blocks of the B-ALL protocol (rituximab, methotrexate, ifosfamide, etoposide, cytarabine, vincristine, cyclophosphamide, doxorubicine, vindesine, dexamethasone).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (R-)CHOP protocol
Description: Patients with a negative interim-PET scan assigned to arm A1 will receive another four cycles of the (R-)CHOP regimen (rituximab, cyclophosphamide, doxorubicine, vincristine, prednisone). Arm A1 was closed when the number of patients required for the randomisation between arms A1 and A2 was reached.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (R-)CHOP protocol
Description: Patients with a negative interim-PET scan assigned to arm A2 will receive another four cycles of the (R-)CHOP regimen (rituximab, cyclophosphamide, doxorubicine, vincristine, prednisone) plus two additional doses rituximab. Since the number of patients required for the randomisation between arms A1 and A2 has been reached, all patients with a negative interim-PET scan are treated according to arm A2.
Study: NCT02622425

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PD01
Description: Carotenoid-producing Bacillus strain PD01
Study: NCT02695043

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: RRTBIMS
Description: TBI patients discharged from Bellevue inpatient rehabilitation and enrolled in the Rusk Rehabilitation Traumatic Brain Injury Model System (RRTBIMS)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimedia Multicultural Educational Program for TBI (MMEPT)
Study: NCT02634645

Intervention type: PROCEDURE
Intervention: Endoscopic eradication therapies (EET)
Description: Endoscopic eradication therapies (EET) includes endoscopic mucosal resection (EMR), which describes the process by which the area most likely to harbor highest grade of dysplasia/neoplasia is removed; radiofrequency ablation (RFA), which describes the process by which Barrett's segments are removed via burning/ablation; and cryotherapy.

Intervention type: PROCEDURE
Intervention: Esophagectomy
Description: The esophagus is surgically removed

Intervention type: DRUG
Intervention: Chemotherapy
Description: Chemical substances are used to treat cancer

Intervention type: RADIATION
Intervention: Radiation
Description: Cancer cells are destroyed by radiation therapy.
Study: NCT01819415

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Anti-VEGF plus AREDS-2
Description: Omega-3 metabolites supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Anti-VEGF plus AREDS-1
Description: Patients receiving intravitreal anti-VEGF and AREDS-1 supplementation plus Lutein, without Omega-3.
Study: NCT04029740

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT- both internet and face to face
Description: There are a few common psychotherapies for treating PD, with Cognitive Behavioral Therapy (CBT) as the most common. The most known type of CBT for treating PD consists of two major strategies: cognitive restructuring, and interoceptive and structured exposure to bodily sensations that have become associated with panic attacks (D H Barlow, 1997). The ICBT therapy is based on Barlow and Craske's (2007) protocol for treating PD with elaborations (Huppert \& Baker-Morissette, 2003). It includes six modules containing psychoeducation, cognitive restructuring, exposures, acceptance, and consolidation of gains and relapse prevention. The online modules include reading passages, worksheets, videos, and homework assignments. After completing each module, participants practice related skills and complete homework assignments. The treatment is up to 16 weeks long; participants are encouraged to complete the treatment within this time period, and reminders are sent to monitor their progress.

Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: Healthy controls will not receive any intervention.
Study: NCT04510337

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard rocuronium dose
Description: 0.6 mg/kg rocuronium during induction of anesthesia
Study: NCT03371225

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active Exercise
Description: Participants will walk briskly in a treadmill (as to keep at 60-70% maximum heart rate) for 30 minutes

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Active tDCS: A 1x1 Low-intensity DC Stimulator will be used to deliver direct current through rubber electrodes in saline soaked sponges. The anode will be placed over the left primary motor cortex (M1) while the cathode will be placed over the contralateral supra-orbital area. Only 30 seconds of current will be applied for the sham condition.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham tDCS
Description: Active tDCS: A 1x1 Low-intensity DC Stimulator will be used to deliver direct current through rubber electrodes in saline soaked sponges. The anode will be placed over the left primary motor cortex (M1) while the cathode will be placed over the contralateral supra-orbital area. Only 30 seconds of current will be applied for the sham condition.
Study: NCT04510337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Description: 50 mg/kg magnesium sulphate added to 0.40 mg/kg rocuronium
Study: NCT01562743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPM 962
Description: Tansdermal patch
Study: NCT03454243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RXDX-106
Description: Patients will receive continuous daily oral doses of RXDX-106 in 21 day cycles. To determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D), study drug will be administered in an escalated fashion starting at dose of 10 mg/day and will proceed at the dose levels prespecified by the dose escalation schema. Once daily dosing for RXDX-106 will initially be tested. However, other dosing schedules (eg, every other day, weight based, etc) may be tested based on safety and PK data to optimize drug exposure.
Study: NCT03667326

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin tablet
Description: Low dose aspirin, 81mg tablets, PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo oral capsule, PO
Study: NCT00423644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darinaparson
Description: 420 mg/m2 of Darinaparsin given twice weekly for three weeks, followed by one week of rest for up to six months
Study: NCT00367237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab + methotrexate (IFX + MTX)
Description: Infliximab 5 mg/kg infusion at Weeks 0, 2, 6, 14 and oral methotrexate 15 mg/week for 16 weeks. Methotrexate dose can be increased to 20 mg/week at week 6.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate (MTX)
Description: Oral methotrexate 15 mg/week for 15 weeks. Dose can be increased to 20 mg/week at Week 6.
Study: NCT02368886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobetasol Propionate
Description: Given topically

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobetasol Propionate
Description: Given topically

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobetasol Propionate
Description: Given topically

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobetasol Propionate
Description: Given topically

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Given PO
Study: NCT03465111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACTH (adrenocorticotropic hormone) gel
Description: The dose of H.P. Acthar Gel is 80 Units administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACTH (adrenocorticotropic hormone) gel
Description: The dose of H.P. Acthar Gel is 80 Units administered subcutaneously
Study: NCT02728219

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: In this study we prospectively select some early diagnosed recurrent HCC patients after radical resection with AFP conversion, then they will be treated with transcatheter arterial chemoembolization (TACE)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hepatectomy
Description: Repeat Hepatectomy after postoperation recurrence
Study: NCT02512146

Intervention type: PROCEDURE
Intervention: colonoscopy
Description: Patients will undergo colonoscopy and participants will get biopsies from the colon.

Intervention type: PROCEDURE
Intervention: colonoscopy
Description: Patients will undergo colonoscopy and participants will get biopsies from the colon.
Study: NCT03415022

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: computer-based treatment
Description: 30 minute sessions of free viewing of faces and listening to music

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: computer-based treatment
Description: 30 minute sessions of free viewing of faces and listening to music
Study: NCT02205879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01996644

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vs Setraline
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setraline
Description: 250mg DCS
Study: NCT02677246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab, one sub-cutaneous infusion, given within 2 weeks after engraftment defined as neutrophils \> 0,5x10(9)/L and chimerism ≥ 10% of donor origin.~Before starting Denosumab several requirements have to be met: 1) Calcemia and Phosphatemia in the normal ranges, 2) adequate Calcium and Vitamin D intakes according to age.~Biological activity of Denosumab measured by CTX blood level, expected to last for 4 to 6 months after one infusion.~Possibility of subsequent infusions at the same dose level, every 5 to 6 months, for patient remaining on corticotherapy, provided no DLT occurred and provided CTX blood level decreased under the required threshold, after the previous infusions of Denosumab
Study: NCT02219828

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anakinra
Description: 2mg/Kg daily sc up to 100mgday as maximum dose
Study: NCT03371225

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sham Exercise
Description: Participants will walk in a treadmill (as to keep at 10% within their baseline heart rate) for 30 minutes.
Study: NCT02219828

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04317768

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Basic oral health education and motivation
Description: Subjects will receive verbal oral hygiene instructions using a model to demonstrate only once at the beginning of the study, no further motivation or educational seminars will be done.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic oral health education and motivation
Description: Subjects will receive verbal oral hygiene instructions using a model to demonstrate only once at the beginning of the study, no further motivation or educational seminars will be done.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive oral health education and motivation
Description: Subjects will be educated and motivated by an intensive program consisting of verbal instructions, PowerPoint lectures, posters and live demonstrations about oral hygiene instructions and teaching the proper way to brush the teeth. These will be reinforced by the investigator at intervals of 1 week, 1 month, 3 months, 6 months and 1 year.
Study: NCT01094743

Intervention type: DEVICE
Group type: OTHER
Intervention: galyfilcon A prototype lens
Description: Silicone hydrogel contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: galyfilcon A prototype lens
Description: Silicone hydrogel contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: lotrafilcon B lens
Description: Silicon Hydrogel contact lens